Resectable Esophageal Squamous Cell Carcinoma Clinical Trials

7 recruitingLast updated: May 29, 2026

There are 7 actively recruiting resectable esophageal squamous cell carcinoma clinical trials across 2 countries. Studies span Phase 2, Phase 3. Top locations include Nanjing, Jiangsu, China, Chengdu, Sichuan, China, Guangzhou, China. Updated daily from ClinicalTrials.gov.


Resectable Esophageal Squamous Cell Carcinoma Trials at a Glance

7 actively recruiting trials for resectable esophageal squamous cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Nanjing, Chengdu, and Guangzhou. Lead sponsors running resectable esophageal squamous cell carcinoma studies include Mayo Clinic, Ning Jiang, M.D./Ph.D., and Jiangsu Cancer Institute & Hospital.

Browse resectable esophageal squamous cell carcinoma trials by phase

Treatments under study

About Resectable Esophageal Squamous Cell Carcinoma Clinical Trials

Looking for clinical trials for Resectable Esophageal Squamous Cell Carcinoma? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Resectable Esophageal Squamous Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Resectable Esophageal Squamous Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC

Esophageal Squamous Cell CarcinomaLocally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sichuan University118 enrolled1 locationNCT07519486
Recruiting
Phase 2

Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Ning Jiang, M.D./Ph.D.98 enrolled1 locationNCT07530094
Recruiting
Phase 2

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

Resectable Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital46 enrolled1 locationNCT07457528
Recruiting
Phase 2

Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Jiangsu Cancer Institute & Hospital22 enrolled1 locationNCT07435454
Recruiting
Phase 2

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Urothelial CarcinomaEsophageal CarcinomaHepatocellular Carcinoma+28 more
Mayo Clinic50 enrolled1 locationNCT06265285
Recruiting
Phase 2

Neoadjuvant QL1706 Therapy for ESCC

Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Shandong Provincial Hospital32 enrolled1 locationNCT06908382
Recruiting
Phase 3

Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

Resectable Esophageal Squamous Cell Carcinoma
Zhigang Li426 enrolled5 locationsNCT05043688